{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T21:48:16Z","timestamp":1779140896766,"version":"3.51.4"},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018592","name":"Celltrion Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018592","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.cgh.2023.06.023","type":"journal-article","created":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T02:23:10Z","timestamp":1689042190000},"page":"154-163.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Outcome of Biological Therapies and Small Molecules in Ulcerative Proctitis: A Belgian Multicenter Cohort Study"],"prefix":"10.1016","volume":"22","author":[{"given":"Pauline","family":"Lemmens","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edouard","family":"Louis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wouter","family":"Van Moerkercke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lieven","family":"Pouillon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Somers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harald","family":"Peeters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stijn","family":"Vanden Branden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Busschaert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filip","family":"Baert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anneline","family":"Cremer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Potvin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Dewit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnaud","family":"Colard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo","family":"Swinnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy","family":"Lambrecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Claessens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Willandt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pieter","family":"Dewint","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evi","family":"Van Dyck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joao","family":"Sabino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00e9verine","family":"Vermeire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1492-0716","authenticated-orcid":false,"given":"Marc","family":"Ferrante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl A","key":"10.1016\/j.cgh.2023.06.023_bib1","doi-asserted-by":"crossref","first-page":"5A","DOI":"10.1155\/2005\/269076","article-title":"Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology","volume":"19","author":"Silverberg","year":"2005","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.cgh.2023.06.023_bib2","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1572-0241.2000.t01-1-01770.x","article-title":"The natural history of ulcerative proctitis: a multicenter, retrospective study. Gruppo di Studio per le Malattie Infiammatorie Intestinali (GSMII)","volume":"95","author":"Meucci","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2023.06.023_bib3","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3109\/00365521.2013.867360","article-title":"Proximal disease extension and related predicting factors in ulcerative proctitis","volume":"49","author":"Kim","year":"2014","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.cgh.2023.06.023_bib4","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2023.06.023_bib5","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.bpg.2018.05.009","article-title":"The treatment of refractory ulcerative colitis","volume":"32-33","author":"Pineton de Chambrun","year":"2018","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.cgh.2023.06.023_bib6","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1016\/j.cgh.2019.09.049","article-title":"No superiority of tacrolimus suppositories vs beclomethasone suppositories in a randomized trial of patients with refractory ulcerative proctitis","volume":"18","author":"Lie","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.06.023_bib7","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cgh.2017.02.027","article-title":"Efficacy of rectal tacrolimus for induction therapy in patients with resistant ulcerative proctitis","volume":"15","author":"Lawrance","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.06.023_bib8","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.dld.2016.12.001","article-title":"Azathioprine for refractory ulcerative proctitis: a retrospective multicenter study","volume":"49","author":"Mallet","year":"2017","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.cgh.2023.06.023_bib9","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1136\/gut.2010.221127","article-title":"Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial","volume":"60","author":"Reinisch","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2023.06.023_bib10","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","article-title":"Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis","volume":"142","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.06.023_bib11","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1053\/j.gastro.2013.05.048","article-title":"Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.06.023_bib12","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1053\/j.gastro.2013.06.010","article-title":"Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.06.023_bib13","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2023.06.023_bib14","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2023.06.023_bib15","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2023.06.023_bib16","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2023.06.023_bib17","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/ecco-jcc\/jjab218","article-title":"Efficacy of pharmacological agents for ulcerative proctitis: a systematic literature review","volume":"16","author":"Caron","year":"2022","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2023.06.023_bib18","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1111\/j.1365-2036.2010.04293.x","article-title":"Infliximab for refractory ulcerative proctitis","volume":"31","author":"Bouguen","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2023.06.023_bib19","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1177\/2050640620941345","article-title":"Long-term outcomes of patients with ulcerative proctitis: analysis from a large referral centre cohort","volume":"8","author":"Dubois","year":"2020","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.cgh.2023.06.023_bib20","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.cgh.2019.05.060","article-title":"Efficacy of tumor necrosis factor antagonist treatment in patients with refractory ulcerative proctitis","volume":"18","author":"Pineton de Chambrun","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.06.023_bib21","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies","volume":"401","author":"Sandborn","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2023.06.023_bib22","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.clinthera.2018.07.013","article-title":"Treatment patterns and sequencing in patients with inflammatory bowel disease","volume":"40","author":"Brady","year":"2018","journal-title":"Clin Ther"},{"key":"10.1016\/j.cgh.2023.06.023_bib23","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/ibd\/izz001","article-title":"Real-world pattern of biologic use in patients with inflammatory bowel disease: treatment persistence, switching, and importance of concurrent immunosuppressive therapy","volume":"25","author":"Chen","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2023.06.023_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0227914","article-title":"Treatment patterns among patients with moderate-to-severe ulcerative colitis in the United States and Europe","volume":"15","author":"Armuzzi","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.cgh.2023.06.023_bib25","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","article-title":"Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2023.06.023_bib26","doi-asserted-by":"crossref","first-page":"293","DOI":"10.4291\/wjgp.v5.i3.293","article-title":"Predictors of response to anti-tumor necrosis factor therapy in ulcerative colitis","volume":"5","author":"Zampeli","year":"2014","journal-title":"World J Gastrointest Pathophysiol"},{"key":"10.1016\/j.cgh.2023.06.023_bib27","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1111\/apt.14665","article-title":"High body mass index is associated with increased risk of treatment failure and surgery in biologic-treated patients with ulcerative colitis","volume":"47","author":"Kurnool","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2023.06.023_bib28","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/s41395-018-0104-x","article-title":"Obesity and response to infliximab in patients with inflammatory bowel diseases: pooled analysis of individual participant data from clinical trials","volume":"113","author":"Singh","year":"2018","journal-title":"Am J Gastroenterol"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356523005293?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356523005293?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:44:22Z","timestamp":1761543862000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356523005293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S1542356523005293"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2023.06.023","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcome of Biological Therapies and Small Molecules in Ulcerative Proctitis: A Belgian Multicenter Cohort Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2023.06.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the AGA Institute","name":"copyright","label":"Copyright"}]}}